The company has also mentioned an exceptional item of Rs 2.2 crore providing for fine related to Perindopril litigation
Pharma major Lupin has reported a net profit of Rs 289.6 crore in Q4FY19 against loss of Rs 783.5 crore in the same quarter last fiscal.
Revenue of the company was up 9.2 percent at Rs 4,406.3 crore versus Rs 4,033.8 crore.
Tax expense for the quarter stood at Rs 300 crore against tax write-back of Rs 163 crore.
Earnings before interest, tax, depreciation and amortization (EBITDA) rose 12 percent to Rs 958.8 crore.
The company has also mentioned an exceptional item of Rs 2.2 crore providing for fine related to Perindopril litigation.
The board of directors recommended a dividend of Rs 5 per equity share.
The company's North America sales were up 16.1%, YoY and up 22.8 percent, QoQ. On the other hand, emerging market sales were down 3.3%, YoY and up 21.3 percent QoQ.
India sales were up 9.1 percent, while Asia Pacific sales were up 4 percent, YoY.At 1502 hours, Lupin was quoting at Rs 797.00, down Rs 12.15, or 1.50 percent.
Get Lok Sabha 2019 Live Election Results, constituency-wise tally, news, views and analysis
Follow our Lok Sabha Election Result Live Blog here.